公开(公告)号：EP2797875A1

公开(公告)日：2014-11-05

申请号：EP12863933.3

申请日：2012-12-19

Applicant: Pharmacyclics, Inc.

Inventor： VERNER, Erik ,  CHEN, Wei ,  BALASUBRAMANIAN, Sriram

IPC: C07C235/34 ,  A61K31/16 ,  A61P43/00

CPC classification number: C07D405/06 ,  C07C235/34 ,  C07C235/38 ,  C07C259/06 ,  C07C311/08 ,  C07D211/42 ,  C07D211/46 ,  C07D213/30 ,  C07D213/36 ,  C07D213/65 ,  C07D213/68 ,  C07D213/82 ,  C07D213/89 ,  C07D295/088 ,  C07D401/06

Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activy of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.

公开(公告)号：EP2755648A1

公开(公告)日：2014-07-23

申请号：EP11872389.9

申请日：2011-09-13

Applicant: Pharmacyclics, Inc. ,  Les Laboratoires Servier SAS

Inventor： LOURY, David, J. ,  BUGGY, Joseph, J. ,  MODY, Tarak, D. ,  VERNER, Erik, J. ,  PURRO, Norbert ,  BALASUBRAMANIAN, Sriram ,  KLOOS, Ioana ,  DEPIL, Stéphane

IPC: A61K31/343 ,  A61K31/166 ,  A61K31/16 ,  A61P35/00

CPC classification number: A61K31/343 ,  A61K9/14 ,  A61K9/28 ,  A61K9/70 ,  A61K31/4184 ,  A61K2300/00

Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.

公开(公告)号：EP2107911A1

公开(公告)日：2009-10-14

申请号：EP08728620.9

申请日：2008-01-30

Applicant: PHARMACYCLICS, INC.

Inventor： BUGGY, Joseph, J. ,  BALASUBRAMANIAN, Sriram

IPC: A61K49/00 ,  C12Q1/68 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  C07H21/04 ,  C12N5/0693 ,  C12N15/11 ,  C12N2503/02 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57419 ,  G01N33/57492 ,  G01N2800/52

Abstract: [00153] Described herein are methods and compositions for determining whether a particular cancer is resistant to or susceptible to a histone deacetylase inhibitor or to histone deacetylase inhibitors. The methods include analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are methods and compositions for increasing the likelihood of a therapeutically effective treatment in a patient, comprising an analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are isolated populations of nucleic acids derived from a cancer sensitive to or resistant to a histone deacetylase inhibitor. Further described are kits and indications that are used in conjunction with the aforementioned methods and compositions.